Skip to main content

Innovent Biologics

Innovent Biologics, Inc. is a Chinese biopharmaceutical enterprise that researches, develops, manufactures, and commercializes innovative medicines for the treatment of major life-threatening diseases. The company directs its scientific focus primarily toward oncology, metabolic diseases, autoimmune disorders, and ophthalmology. Its principal product offerings encompass monoclonal antibodies, immunotherapies, and other biologic therapeutic products approved for clinical application. Revenue is driven primarily by the commercial sale of approved pharmaceutical products within domestic markets, alongside licensing fees and collaborative development agreements with global pharmaceutical partners. The primary end markets comprise hospitals, clinics, and patients requiring advanced biologic therapies. As a prominent participant in the expanding Asian biotechnology sector, the enterprise maintains substantial research and manufacturing capabilities. Headquartered in Suzhou, China, Innovent Biologics, Inc. is publicly listed on the Hong Kong Stock Exchange.

44 of the funds FundTelligence covers report a position in Innovent Biologics.

Legal name
Innovent Biologics Inc
Sector
Health Care
Country
China
Funds holding it
44

Funds holding Innovent Biologics

Showing the 8 largest of 44 funds holding it.

Loading...